Quick Answer
Verrica Pharmaceuticals Inc. reported R&D Expense of $8.86 million for fiscal year 2025.
Verrica Pharmaceuticals Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $8.86M | -25.2% |
| 2024 | $11.84M | -41.7% |
| 2023 | $20.30M | +351.0% |
| 2023 | $4.50M | -63.1% |
| 2022 | $12.20M | -23.4% |
| 2021 | $15.93M | +1.6% |
| 2020 | $15.67M | +1.5% |
| 2019 | $15.44M | +20.3% |
| 2018 | $12.83M | +243.9% |
| 2017 | $3.73M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.21M | -8.3% | +19.4% |
| June 30, 2025 | $1.85M | -44.4% | -19.2% |
| March 31, 2025 | $2.28M | -53.8% | -5.0% |
| September 30, 2024 | $2.40M | -63.1% | -27.5% |
| June 30, 2024 | $3.32M | -42.0% | -32.9% |
| March 31, 2024 | $4.95M | +80.6% | -24.0% |
| September 30, 2023 | $6.51M | +134.2% | +44.7% |
| July 31, 2023 | $4.50M | — | -21.4% |
- Verrica Pharmaceuticals Inc. showed a decrease of -25.2% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Verrica Pharmaceuticals Inc.’s r&d expense has grown by 137.4% (from $3.73 million to $8.86 million).
- The most recent figure is from Verrica Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: